Foghorn Therapeutics (FHTX) 2025 Conference June 05, 2025 03:45 PM ET Speaker0 Good afternoon, everyone. Thank you for attending Jefferies Global Healthcare Conference. My name is Kelly Xu, one of the senior analysts on biotech team. And for this first set of chat session, we are very pleased to have mister Andrew Gostrok, Chief Executive Officer from Falkhawn Therapeutics. Welcome. Speaker1 Thank you. Speaker0 Maybe first we could recap the potential in addressing the chromatin regulatory system and the BA ...

CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen’s 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Commission File Number: 001-39634 ______________________ Foghorn Therapeutics Inc. (Exact Name of Registrant as Specified in its Charter) ______________________ FORM 10-Q _____________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ...

Exhibit 99.1 Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical exploration Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026 Continued progress ...

CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Citizens Life Sciences Conference, being held May 7-8, 2025, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the ...

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. “Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry,” said Adrian Gottschalk, President and Chief E ...

Foghorn Therapeutics (FHTX) FY 2025 Conference April 29, 2025 01:00 PM ET Speaker0 Good morning and welcome to the Foghorn Pipeline Update Conference Call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this webcast is being recorded today, 04/29/2025. I will now turn the call over to Karen Helzvik, VP of Investor Relations and Corporate Affairs. Please go ahead. Speaker1 Thank you everyone f ...

AACR April 2025 April 29, 2025 • Targeting SMARCA2-Dependent Tumors with FHD-909 (LY4050784) • Advancing Multiple Additional First-in-Class Anticancer Agents Forward Looking Statements This presentation contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements other than statements of historical facts contained in this presentation are forward- looking statements. In some cases, you can identify forward-loo ...

- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS inhibitors supports clinical exploration - Selective CBP degrader combination approaches show promise in preclinical ER+ breast cancer models - Further preclinical characterization of the therapeutic potential of the Selective EP300 degrader program to t ...

文章核心观点 - 公司Etiome由Flagship Pioneering创立，其Temporal Biodynamics™平台是首个端到端检测疾病并在病情恶化前进行干预的技术，可加速预防性药物开发，改善慢性病和进行性疾病患者健康状况 [1][7] 公司相关信息 Etiome - 公司由Flagship Pioneering于2021年创立，获其5000万美元初始投资，致力于重新定义疾病检测和预防方式，开发预防性药物 [1][7] - 团队成员包括生物学、组学和人工智能领域专家，如Avak Kahvejian、Scott Lipnick等 [2][4] - 平台结合多模态数据和人工智能，能准确表征疾病生物阶段，识别患者并开发针对性药物，最初聚焦代谢、神经退行性、癌前和自身免疫性疾病 [2][3] Flagship Pioneering - 生物平台创新公司，自2000年成立以来发起并培育超100个科研项目，总价值超600亿美元，管理资产达140亿美元 [8] - 旗下生态系统包含超40家公司，如Foghorn Therapeutics、Moderna等 [8] Flagship Preemptive Health and Medicine - 开创预防性健康和医学新领域，旨在在人们患病前保护、维持或改善健康，利用计算和生命科学进展预测和检测疾病并进行干预 [6]